Guadecitabine-话题@MedSci - 梅斯（MedSci）

#Guadecitabine#

8篇内容 | 1119人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1588652, encodeId=941c1588652a4, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, objectType=article, longId=726160, objectId=eab4e261604e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab4e261604e, replyNumber=0, likeNumber=71, createdTime=2022-05-06, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab4e261604e, moduleTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=eab4e261604e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588651, encodeId=ffc8158865123, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, objectType=article, longId=724945, objectId=a43ee2494583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a43ee2494583, replyNumber=0, likeNumber=71, createdTime=2022-04-26, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a43ee2494583, moduleTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a43ee2494583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588650, encodeId=8c0c158865029, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, objectType=article, longId=207297, objectId=95e820e29758, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95e820e29758, replyNumber=0, likeNumber=80, createdTime=2021-02-20, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95e820e29758, moduleTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=95e820e29758)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588649, encodeId=745715886499b, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, objectType=article, longId=165485, objectId=0adb1654850e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0adb1654850e, replyNumber=0, likeNumber=77, createdTime=2019-05-08, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0adb1654850e, moduleTitle=Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0adb1654850e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588648, encodeId=2108158864833, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, objectType=article, longId=165382, objectId=9da8165382e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9da8165382e2, replyNumber=0, likeNumber=0, createdTime=2019-05-06, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9da8165382e2, moduleTitle=Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9da8165382e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588647, encodeId=4241158864e6e, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, objectType=article, longId=145679, objectId=d3dd1456e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3dd1456e979, replyNumber=0, likeNumber=69, createdTime=2018-08-03, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3dd1456e979, moduleTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d3dd1456e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588646, encodeId=aefd158864626, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, objectType=article, longId=139686, objectId=ff45139686f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff45139686f9, replyNumber=0, likeNumber=65, createdTime=2018-06-03, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff45139686f9, moduleTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ff45139686f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588645, encodeId=48801588645bd, content=<a href='/topic/show?id=57fe831e70' target=_blank style='color:#2F92EE;'>#Guadecitabine#</a>, objectTitle=Lancet oncol：Guadecitabine（SCI-100）的不同剂量和用药时间用于首次治疗的急性髓性白血病老年患者的安全性和有效性。, objectType=article, longId=110853, objectId=827611085371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=827611085371, replyNumber=0, likeNumber=72, createdTime=2017-08-27, rootId=0, userName=licz0429, userId=bcac17601956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=827611085371, moduleTitle=Lancet oncol：Guadecitabine（SCI-100）的不同剂量和用药时间用于首次治疗的急性髓性白血病老年患者的安全性和有效性。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=827611085371)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Guadecitabine

2020-05-29

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估

2022-05-06

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性

2022-04-26

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤

2021-02-20

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Lancet Haematology.：Guadecitabine用于中高危骨髓增生异常综合征

2019-05-08

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Lancet Haemat：Guadecitabine用于中高危骨髓增生异常综合征患者的疗效和安全性

2019-05-06

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点

2018-08-03

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌

2018-06-03

licz0429 (审核中...)

前往app查看评论内容

#Guadecitabine#

Lancet oncol：Guadecitabine（SCI-100）的不同剂量和用药时间用于首次治疗的急性髓性白血病老年患者的安全性和有效性。

2017-08-27

科室
- - 订阅+
  - 更多科室
工具
服务